FIG. 6.

rmGM-CSF augments the protective effect of low-dose amphotericin B. Fungal recovery from lungs (A) and spleens (B) of mice (n = 6) challenged with 1.25 × 10⁷ yeast cells and treated with amphotericin B (0.125 mg/kg/day) plus diluent or amphotericin B plus rmGM-CSF. Survival (n = 10) is depicted in panel C. (D and E) CFU in lungs (D) and spleens (E) of CD4⁺ CD8⁺ cell-deficient mice treated with amphotericin B plus diluent or amphotericin B plus rmGM-CSF. Survival of the mice (n = 10) is exhibited in panel F. Data for CFU are expressed as means ± standard errors.